Asthma Drug Fails to Treat Alcoholism Except in Select Group, Study Finds

In recent years, the exploration of neuroimmune modulators as potential therapies for alcohol use disorder (AUD) has captured considerable scientific interest. Among these candidates, ibudilast, a drug originally approved in Japan for the treatment of asthma and post-stroke dizziness, emerged as a promising intervention due to its anti-inflammatory properties. Researchers hypothesized that by targeting neuroinflammation, ibudilast could mitigate the neurobiological underpinnings of AUD, thereby reducing alcohol consumption. However, a groundbreaking clinical trial conducted by the UCLA Addictions Lab has challenged this optimistic view, revealing nuanced and complex outcomes that both temper expectations and illuminate new pathways in addiction treatment research.

This comprehensive phase II randomized controlled trial enrolled 102 adults diagnosed with moderate to severe alcohol use disorder. Participants were administered either ibudilast or a placebo twice daily over a 12-week treatment period, followed by a four-week monitoring phase. The study meticulously measured several drinking behavior metrics including the percentage of heavy drinking days, average drinks per drinking day, and percent days abstinent. Additionally, assessments of depressive symptoms and inflammatory biomarkers were integrated to understand the differential biological and psychological responses to treatment.

The overarching result was sobering: ibudilast did not significantly outperform placebo across the entire cohort in reducing alcohol consumption. Both groups exhibited a meaningful decline in drinking levels over the treatment span, with the average number of drinks per drinking day dropping from approximately seven to between three and four. This robust placebo effect highlights an entrenched challenge in addiction medicine research — the difficulty in disaggregating true pharmacological effects from the multifaceted psychosocial influences and expectancy effects inherent in clinical trial settings.

Notwithstanding the overall null findings, the study unveiled a compelling sex-specific response pattern. Female participants exhibited a statistically significant reduction in drinks per drinking day when treated with ibudilast compared to placebo. This differential efficacy aligns with emerging data that women generally manifest higher basal levels of systemic inflammation than men, possibly making them more responsive to treatments targeting neuroimmune pathways. The observation that ibudilast’s anti-inflammatory actions may underlie this sex-dependent benefit marks an important development in understanding AUD’s heterogeneity and tailoring personalized treatment protocols.

Conversely, participants presenting with elevated depressive symptoms at baseline paradoxically fared worse on ibudilast compared to placebo. This complex interaction between mood disorders and immune-modulating pharmacotherapies underscores the intricate neurobiological interplay between psychiatric comorbidities and addiction. Depression’s known association with dysregulated immune signaling might modulate drug efficacy negatively, suggesting that co-occurring psychiatric profiles are critical variables in assessing candidate AUD medications and require careful stratification in future trials.

Despite targeting neuroimmune mechanisms, ibudilast did not significantly reduce peripheral biomarkers of inflammation in this study. This unexpected outcome raises pivotal questions about the drug’s mechanism of action in the context of AUD and the adequacy of measuring systemic inflammatory markers to infer central nervous system effects. The blood-brain barrier’s selective permeability and regional neuroimmune dynamics may mean that peripheral inflammatory assays inadequately capture the nuanced immunomodulatory processes relevant to addiction pathophysiology.

The trial’s investigators, led by UCLA psychology professor Lara Ray, emphasized the necessity of longer-duration studies to further distinguish the sustained effects of ibudilast from initial placebo-mediated improvements. Treatment efficacy in AUD often requires extended evaluation beyond conventional 12-week trials to observe enduring decreases in alcohol use and relapse prevention. Indeed, the current findings advocate for larger, sex-stratified studies with prolonged follow-ups to better elucidate ibudilast’s therapeutic potential and target populations.

Importantly, this research reiterates the emerging paradigm that immune system dysregulation plays a significant role in substance use disorders. Neuroinflammation is increasingly recognized as a crucial contributor to the neurocircuitry alterations that reinforce compulsive alcohol consumption. The possibility that immunomodulatory agents such as ibudilast and apremilast could revolutionize AUD treatment mirrors the transformative effects these therapies have had in oncology, where targeting immune checkpoints has reshaped clinical outcomes.

Moreover, the results highlight the critical importance of integrating multidimensional phenotyping, including inflammatory status and psychiatric comorbidities, in clinical trials for addiction medications. Personalized medicine approaches, guided by biomarker profiles and symptomatic clusters, could optimize therapeutic outcomes by matching patients with interventions tailored to their neuroimmune and emotional landscapes.

The trial’s robust methodology, carefully tracking drinking behaviors alongside psychological and biological parameters, provides a rich dataset for ongoing analyses. Future investigations promise to clarify which subpopulations, such as individuals with comorbid chronic pain or elevated inflammation, might gain the most from ibudilast treatment. These precision medicine insights are expected to shape the next wave of innovation in AUD therapeutics, moving beyond one-size-fits-all approaches.

While the disappointing overall lack of superiority over placebo underscores the formidable challenges in developing pharmacotherapies for alcohol use disorder, the positive signals observed in women inject cautious optimism. They prompt a reevaluation of neuroimmune targets and gender-specific biology in addiction science. As Professor Ray notes, understanding who responds and why remains an imperative scientific quest, one with profound implications given that nearly 30 million adults in the United States suffer from AUD.

The trial was supported by the National Institute on Alcohol Abuse and Alcoholism, reflecting sustained federal commitment to combating a pervasive and costly public health issue. As laboratories worldwide continue to explore the interface of neuroimmunology and addiction, the nuanced findings from the UCLA Addictions Lab’s ibudilast study serve as both a cautionary tale and a beacon guiding future inquiry. With innovative trial designs, biomarker integration, and longer follow-up periods, the path forward appears promising, offering hope for novel, effective medications for those battling the disease of alcoholism.

Ultimately, the translation of immune-targeting therapies from cancer immunotherapy to psychiatric conditions like AUD represents a frontier of neuropsychopharmacology. While ibudilast’s journey from hopeful candidate to nuanced outcome illustrates the complexity of addiction biology, it also expands our conceptual frameworks. The ongoing quest to disentangle the neuroimmune contributions to alcohol use disorder continues, underscoring the dynamism and rigor required to develop transformative treatments that can reduce the massive societal burden of addiction.

News Publication Date: Not explicitly stated; article references publication in JAMA Network Open

Web References:

• UCLA Addictions Lab: https://addictions.psych.ucla.edu/
• JAMA Network Open article: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2833329
• Prior ibudilast research: https://addictions.psych.ucla.edu/wp-content/uploads/sites/160/2018/01/NPP-Development-of-the-neuroimmune-modulator-ibudilast-for-the-treatment-of-alcoholism-A-randomized-placebo-controlled-human-laboratory-trial.pdf OR https://pubmed.ncbi.nlm.nih.gov/34585396/

References: Included research articles as above